G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)

Stock Information for Black Diamond Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Black Diamond Therapeutics Inc.

Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GTHX, OBDC, PETQ on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GVP, PETQ, GTHX on Behalf of Shareholders
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Thoughtworks Holding, Inc. (Nasdaq - TWKS), PetIQ, Inc. (Nasdaq - PETQ), G1 Therapeutics, Inc. (Nasdaq - GTHX), GSE Solutions, Inc. (Nasdaq - GVP)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BAYA, RCFA, OBDC, GTHX on Behalf of Shareholders
GTHX SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Tender Offer of G1 Therapeutics, Inc.
G1 THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of G1 Therapeutics, Inc. - GTHX
Kuehn Law Encourages BAYA, RCFA, OBDC, and GTHX Investors to Contact Law Firm

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.